MediPharm Labs Corp.
MEDIF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41,961 | $33,062 | $22,117 | $21,711 |
| % Growth | 26.9% | 49.5% | 1.9% | – |
| Cost of Goods Sold | $29,156 | $27,207 | $24,031 | $36,957 |
| Gross Profit | $12,805 | $5,855 | -$1,914 | -$15,246 |
| % Margin | 30.5% | 17.7% | -8.7% | -70.2% |
| R&D Expenses | $235 | $209 | $1,002 | $1,355 |
| G&A Expenses | $19,812 | $21,635 | $18,453 | $18,402 |
| SG&A Expenses | $22,856 | $24,796 | $24,757 | $23,033 |
| Sales & Mktg Exp. | $3,044 | $3,161 | $6,304 | $4,631 |
| Other Operating Expenses | $523 | -$898 | $1,118 | $3,375 |
| Operating Expenses | $23,614 | $24,107 | $26,877 | $27,763 |
| Operating Income | -$10,809 | -$18,252 | -$29,533 | -$48,916 |
| % Margin | -25.8% | -55.2% | -133.5% | -225.3% |
| Other Income/Exp. Net | $115 | $4,893 | -$456 | -$5,772 |
| Pre-Tax Income | -$10,694 | -$13,359 | -$29,989 | -$54,688 |
| Tax Expense | $0 | -$276 | -$6 | $113 |
| Net Income | -$10,694 | -$13,083 | -$29,983 | -$54,801 |
| % Margin | -25.5% | -39.6% | -135.6% | -252.4% |
| EPS | -0.026 | -0.036 | -0.11 | -0.22 |
| % Growth | 27.2% | 67.3% | 50% | – |
| EPS Diluted | -0.026 | -0.036 | -0.11 | -0.22 |
| Weighted Avg Shares Out | 407,993 | 363,324 | 276,861 | 249,907 |
| Weighted Avg Shares Out Dil | 407,993 | 363,324 | 276,861 | 249,907 |
| Supplemental Information | – | – | – | – |
| Interest Income | $691 | $840 | $479 | $225 |
| Interest Expense | $576 | $365 | $31 | $10,506 |
| Depreciation & Amortization | $2,600 | $2,516 | $4,093 | $11,765 |
| EBITDA | -$7,518 | -$10,478 | -$25,440 | -$38,549 |
| % Margin | -17.9% | -31.7% | -115% | -177.6% |